JP Morgan Upgrades Biogen to Overweight, Raises Price Target to $300

Benzinga · 2d ago
JP Morgan analyst Chris Schott upgrades Biogen (NASDAQ:BIIB) from Neutral to Overweight and raises the price target from $210 to $300.